BOSTON, MA, United States of America

Anoop P Patel

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The General Hospital Corporation. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anoop P Patel: Innovator in Glioblastoma Treatment

Introduction

Anoop P Patel is a prominent inventor based in Boston, MA, known for his significant contributions to the field of medical research. He has focused on developing innovative treatments for drug-tolerant glioblastoma, a challenging form of brain cancer. His work aims to improve patient outcomes and advance the understanding of glioblastoma stem cells.

Latest Patents

Anoop P Patel holds a patent for "Compositions and methods for treating drug-tolerant glioblastoma." This invention provides compositions and methods specifically designed for the treatment of drug-tolerant glioblastoma, particularly targeting glioblastoma stem cells. The methods involve contacting a glioblastoma stem cell with a platelet-derived growth factor receptor alpha inhibitor, along with one or more of a histone lysine demethylase inhibitor and a Notch inhibitor. He has 1 patent to his name.

Career Highlights

Anoop P Patel is affiliated with The General Hospital Corporation, where he conducts his research and development efforts. His work has garnered attention for its potential to revolutionize treatment options for patients suffering from glioblastoma.

Collaborations

He collaborates with esteemed colleagues, including Bradley Bernstein and Cem Sievers, who contribute to the research and development of innovative treatment strategies.

Conclusion

Anoop P Patel's work in the field of glioblastoma treatment exemplifies the impact of innovative research on healthcare. His contributions are paving the way for new therapeutic approaches that could significantly benefit patients facing this aggressive cancer.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…